A controversial analysis of US registry data suggesting worse outcomes with the Impella percutaneous left ventricular assist device (Abiomed) versus an intra-aortic balloon pump (IABP) in patients ...
The data source has significant limitations, containing just a fraction of Impella patients and unable to delineate between common adverse events The Impella patients were much sicker and had greater ...
MADRID, Aug. 31, 2025 /PRNewswire/ --Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously ...
PHILADELPHIA -- The Impella mechanical support device, frequently used in patients in cardiogenic shock who are undergoing percutaneous coronary interventions, was more expensive than intra-aortic ...
Impella heart pump upgraded to Class 2a in ACC/AHA treatment guideline for cardiogenic shock secondary to STEMI DANVERS, Mass., March 27, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, the global ...
Over 3,000 U.S. Patients Have Received Higher Flow Impella CP DANVERS, Mass., (GLOBE NEWSWIRE) -- Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported that ...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) is committed to improving patient outcomes by performing FDA studies and post-market surveillance, collecting real-world evidence and ...
DANVERS, Mass., March 27, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella® heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results